Table 3 Results after first-line treatment.
From: Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up
Cladribine | Pentostatin | “Other” treatments | All treated patients | |
|---|---|---|---|---|
Follow-up (months), median (range) | 116 (21–293) | 126 (2–292) | 221 (3–413) | 128 (2–413) |
ORR, n (%) | 157 (99) | 45 (100) | 52 (96) | 255 (99) |
CR, n (%) | 131 (83) | 38 (84) | 32 (58) | 201 (78) |
Median RFS (months) | 163 | 159 | 55 | 136 |
CIR | ||||
1 year (%) | 2.5 | 4.4 | 5.5 | 3.5 |
5 years (%) | 14 | 13 | 49 | 21 |
10 years (%) | 33 | 30 | 66 | 39 |
Median OS (months) | NR | NR | 328 | 321 |
OS, evaluable patients | ||||
1 year, n (%) | 100 (158) | 96 (47) | 98 (57) | 99 (263) |
5 years, n (%) | 97 (150) | 86 (42) | 95 (54) | 95 (246) |
10 years, n (%) | 94 (77) | 81 (25) | 89 (43) | 90 (145) |
20 years, n (%) | 69 (8) | 71 (3) | 82 (26) | 76 (37) |
